{"_id":{"$oid":"5c738bef4020a31f3e84e547"},"slug":"module1","created_at":{"$date":"2019-02-25T06:32:15.790Z"},"updated_at":{"$date":"2019-02-25T06:32:15.790Z"},"name":"Module1","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eHistory \u0026amp; Introduction:\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eWilllian Withering FRS \u003c/strong\u003e (17 March 1741 \u0026ndash; 6 October 1799).\u003c/p\u003e\n\n\u003cp\u003eHe has written a book \u0026ldquo;An Account of the\u003c/p\u003e\n\n\u003cp\u003eFoxglove and Some of its Medicinal Uses: With\u003c/p\u003e\n\n\u003cp\u003ePractical Remarks on Dropsy and Other Diseases\u0026rdquo;.\u003c/p\u003e\n\n\u003cp\u003eExplained the events developed after the large doses of foxglove (source of digoxin).\u003c/p\u003e\n\n\u003cp\u003eThe alarming sign for the regulations of drugs:\u003c/p\u003e\n\n\u003cp\u003eThalidomide disaster.\u003c/p\u003e\n\n\u003cp\u003eThalidomide drug is given for nausea in pregnancy and lead to thousands of children born with deformity limbs (Phocomelia-seal like limbs)\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003e1961-Dr. McBride, an Australian doctor, wrote a letter to the editor of the Lancet Journal, in which he suggested a connection between congenital malformation of babies and thalidomide.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eDr. Lenz - German Pediatrician- Suggested a co-relation of thalidomide and congenital anomalies and published an article.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eDr. Frances Oldham Kelsey - Pharmacologist and a Physician- The women who struggled hard for thalidomide not to enter into USA market .\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003eThe sulfanilamide tragedy:\u003c/p\u003e\n\n\u003cp\u003e1937:\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe medicine sulphanilamide was prepared as tablets and capsules from pharmaceutical companies and the S.E. Massengill Company of Bristol, Tennessee, decided that a liquid form of sulphanilamide be prepared with composition of 10 percent sulfanilamide, 72 percent diethylene glycol, and 16 percent water.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe composition lead to nearly 107 deaths in the USA, because of the use of sulfanilamide elixir, containing diethyl glycol as the solvent.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e1938:\u003c/p\u003e\n\n\u003cul\u003e\n\u0009\u003cli\u003e\n\u0009\u003cp\u003eThe incident triggered the Food, Drugs and cosmetic act to monitor the safety of new drugs.\u003c/p\u003e\n\u0009\u003c/li\u003e\n\u003c/ul\u003e\n\n\u003cp\u003e1962- USA, Approved an amendment requiring safety and efficacy data of drugs before premarketing submission.\u003c/p\u003e\n\n\u003cp\u003eThis is called as \u0026ldquo;Kafauver Haris Amendment\u0026rdquo;\u003c/p\u003e\n\n\u003cp\u003eInformed consent was required \u0026amp; Adverse drug reaction was required to report FDA.\u003c/p\u003e\n\n\u003cp\u003e1962: Yellow card Scheme was developed by Bill Inman after Thalidomide disaster.\u003c/p\u003e\n\n\u003cp\u003eAdverse reactions are to be reported according to the scheme. It is organized by Medicines and Health care Products Regulatory Agency (MHRA).\u003c/p\u003e\n\n\u003cp\u003eYellow cards are available from pharmacies and a few are in the British National Formulary as tear off pages.\u003c/p\u003e\n\n\u003cp\u003e1965: First Pharmaceutical directive 65/65/EC.\u003c/p\u003e\n\n\u003cp\u003eEuropean legislation developed . European Law requires all medicinal products to obtain a Marketing Authorisation before they are in the EU market.\u003c/p\u003e\n\n\u003cp\u003e\u003cstrong\u003e1966- pilot study of Boston Collaborative Drug Surveillance Program started.\u003c/strong\u003e\u003c/p\u003e\n\n\u003cp\u003eIt was the first group to conduct epidemiologic researches to quantify the potential adverse effects of drugs utilizing in-hospital monitoring and had an essential role in the development and application of methods in drug epidemiology.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e1968-the WHO Programme for International Drug Monitoring was instituted.\u003c/p\u003e\n\n\u003cp\u003eDuring the 16th World assembly there was a call for \u0026ldquo;Systematic collection of adverse drug reactions, once the drug is marketed. ten members participated in this program (Australia, UK, USA, Germany, Canada, Ireland, Sweden, Denmark, New Zealand, and Netherlands).\u003c/p\u003e\n\n\u003cp\u003e1992- the European Society of Pharmacovigilance (ESoP) was established and changed into the International Society of Pharmacovigilance (IsoP).\u003c/p\u003e\n\n\u003cp\u003eESoP- International non profit scientific organization- it strengths the Pharmacovigilance and enhance for safe and proper use of medicines.\u003c/p\u003e\n\n\u003cp\u003eLatet ESoP is changed to ISoP.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e1995- the European Medicines Agency (EMA) was set up.\u003c/p\u003e\n\n\u003cp\u003eThe main aim of EMA is to harmonize the work between the national medicine regulatory bodies.\u003c/p\u003e\n\n\u003cp\u003eOver the course of time EMA has developed regulations to Rare diseases, herbal medicines, herbal medicines and advanced therapy medicines.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e2001-EudraVigilance came into existence.\u003c/p\u003e\n\n\u003cp\u003eIt is the official European database for managing and analysing information on suspected adverse reactions to medicines which have been authorized for the market or being studied in European clinical trials.\u003c/p\u003e\n\n\u003cp\u003e\u003cbr /\u003e\n\u0026nbsp;\u003c/p\u003e\n\n\u003cp\u003e2001-EudraVigilance came into existence.\u003c/p\u003e\n\n\u003cp\u003eIt is the official European database for managing and analysing information on suspected adverse reactions to medicines which have been authorized for the market or being studied in European clinical trials.\u003c/p\u003e\n\n\u003cp\u003e2012- New legislation in European pharmacovigilance (Directive 2010/84/EU).\u003c/p\u003e\n\n\u003cp\u003eThe pharmacovigilance is further amended in order to strengthen the patient safety and well being.\u003c/p\u003e\n\n\u003cp\u003eThe Good Pharmacovigilance practices came into existence.\u003c/p\u003e\n\n\u003cp\u003e2017- The new EudraVigilance format was launched.\u003c/p\u003e\n\n\u003cp\u003eThe updated Pharmacovigilance legislation had significant changes in electronic reporting for suspected adverse drug reactions which supports better safety monitoring of drugs and more efficient system for stakeholders.\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738bf54020a31f3e84e548"},"slug":"module2","created_at":{"$date":"2019-02-25T06:32:21.581Z"},"updated_at":{"$date":"2019-02-25T06:32:21.581Z"},"name":"Module2","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module 2 content\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738bfb4020a31f3e84e549"},"slug":"module3","created_at":{"$date":"2019-02-25T06:32:27.527Z"},"updated_at":{"$date":"2019-02-25T06:32:27.527Z"},"name":"module3","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module3\u0026nbsp;content\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738c014020a31f3e84e54a"},"slug":"module4","created_at":{"$date":"2019-02-25T06:32:33.832Z"},"updated_at":{"$date":"2019-02-25T06:32:33.832Z"},"name":"Module4","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module4\u0026nbsp;content\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738c074020a31f3e84e54b"},"slug":"module5","created_at":{"$date":"2019-02-25T06:32:39.412Z"},"updated_at":{"$date":"2019-02-25T06:32:39.412Z"},"name":"Module5","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module5\u0026nbsp;content\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738c0c4020a31f3e84e54c"},"slug":"module6","created_at":{"$date":"2019-02-25T06:32:44.859Z"},"updated_at":{"$date":"2019-02-25T06:32:44.859Z"},"name":"Module6","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module6\u0026nbsp;content\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738c114020a31f3e84e54d"},"slug":"module7","created_at":{"$date":"2019-02-25T06:32:49.483Z"},"updated_at":{"$date":"2019-02-25T06:32:49.483Z"},"name":"Module7","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module7\u0026nbsp;content\u003c/p\u003e\n","__v":0}
{"_id":{"$oid":"5c738c174020a31f3e84e54e"},"slug":"module8","created_at":{"$date":"2019-02-25T06:32:55.406Z"},"updated_at":{"$date":"2019-02-25T06:32:55.406Z"},"name":"Module8","course_id":{"$oid":"5c70e72a093dbd32c6155519"},"content":"\u003cp\u003eThis is module8\u0026nbsp;content\u003c/p\u003e\n","__v":0}
